Bmf (Bcl-2-modifying factor) is a pro-apoptotic member of the Bcl-2 protein family, which plays a crucial role in the regulation of apoptosis, acting as a sentinel for cellular stress and damage. It functions as a pivotal mediator in the intrinsic apoptotic pathway, contributing to the maintenance of cellular homeostasis by facilitating the elimination of damaged or superfluous cells. Bmf exerts its pro-apoptotic effects by interacting with and neutralizing the function of anti-apoptotic Bcl-2 family members, thus promoting mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and the subsequent activation of caspases. This process is essential for the execution phase of apoptosis. The activity of Bmf is tightly regulated in healthy cells, where it is sequestered in cytoskeletal structures or in association with specific organelles, thereby preventing unwarranted apoptotic signaling. The ability of Bmf to respond to cellular stress and damage underscores its significance in maintaining tissue homeostasis and responding to pathological conditions.
The activation of Bmf is intricately linked to cellular stress responses, including DNA damage, nutrient deprivation, and oxidative stress, which serve as cues for its release from cytoskeletal or organelle anchors and its subsequent engagement in the apoptotic process. Post-translational modifications, such as phosphorylation, play a critical role in regulating Bmf's pro-apoptotic activity. These modifications can alter its conformation, subcellular localization, or affinity for anti-apoptotic Bcl-2 family members, thereby modulating its ability to induce apoptosis. Furthermore, the activation of Bmf can be facilitated through interactions with specific binding partners or by changes in the cellular microenvironment that lead to the disruption of its interactions with cytoskeletal components. This liberation of Bmf enables it to translocate to the mitochondria, where it can exert its pro-apoptotic function. The mechanisms governing Bmf activation are complex and are influenced by a multitude of cellular signals and conditions, reflecting the sophisticated regulatory network that controls apoptosis.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Affects multiple pathways, including sirtuins and AMPK, possibly leading to BMF activation. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor that arrests cell cycle and can cause cellular stress, inducing BMF. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Induces ER stress, which can activate apoptotic pathways and potentially BMF. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Broad-spectrum kinase inhibitor. Known to induce apoptosis, which may involve BMF. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Induces ER stress and activates unfolded protein response, which can activate BMF. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Causes DNA damage, which can lead to activation of apoptosis and possibly BMF. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Topoisomerase inhibitor that induces DNA damage, potentially leading to BMF activation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor that causes protein accumulation and cellular stress, which can activate BMF. | ||||||
Oxaliplatin | 61825-94-3 | sc-202270 sc-202270A | 5 mg 25 mg | $112.00 $394.00 | 8 | |
Causes DNA crosslinking, which can activate apoptotic pathways and potentially BMF. | ||||||